Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has announced it will not seek regulatory approval on another use for one of the key treatments in its cancer portfolio. In a late-stage study, CYRAMZA met its main goal of progression free-survival in patients with certain types of gastric or gastroesophageal cancer, but did not improve a secondary endpoint: overall survival rate.
Lilly Oncology Senior Vice President of Global Development and Medical Affairs Levi Garraway said "while we hoped that the positive PFS outcome would have translated into an OS benefit, these RAINFALL results highlight the challenges associated with improving outcomes for people with advanced gastric cancer. This is underscored by the fact that there have been no major advances over standard chemotherapy in the first-line HER2-negative gastric cancer treatment setting in the last decade. Lilly is deeply committed to patients with this aggressive disease, and CYRAMZA remains a standard of care in the second-line treatment paradigm for advanced gastric cancer patients around the world. We thank the patients, their caregivers and investigators for their support of and participation in the RAINFALL study."
CYRAMZA is currently combined with other medications or used alone in treatment of several illnesses including metastatic non-small cell lung cancer, advanced gastric cancer, gastroesophageal junction cancer and metastatic colorectal cancer.
You can connect to more about the results and CYRAMZA by clicking here.
Source : http://www.insideindianabusiness.com/story/37069687/lilly-cancer-treatment-falls-short-in-study